Difference between revisions of "Trazodone-hypericum"
From Psychiatrienet
| Line 7: | Line 7: | ||
* '''Day 8:''' stop administration of trazodone. | * '''Day 8:''' stop administration of trazodone. | ||
| start = | | start = | ||
| − | * '''Day | + | * '''Day 15:''' start administration of hypericum in a dosage of 300 mg three times a day (900 mg/day).<ref>{{Pubmed|18294328|Imai H, Kotegawa T, Tsutsumi K, Morimoto T, Eshima N, Nakano S, Ohashi K. The recovery time-course of CYP3A after induction by St John's wort administration. Br J Clin Pharmacol. 2008 May;65(5):701-7.}}</ref><ref>{{Pubmed|16640452|Wurglics M, Schubert-Zsilavecz M. Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet. 2006;45(5):449-68.}}</ref><ref>{{Pubmed|19593191|Derijks HJ, Janknegt R, Heerdink ER, De Koning FH, Krekels MM, Looij BJ, Egberts AC. Influence of antidepressant use on glycemic control in patients with diabetes mellitus: an open-label comparative study. J Clin Psychopharmacol. 2009 Aug;29(4):405-8.}}</ref><ref name="informatorium">{{KNMP|trazodon}}</ref> |
| info = | | info = | ||
* The content of trazodone in the tablet, for example 100 mg or 150 mg, determines which exact doses are given. }} | * The content of trazodone in the tablet, for example 100 mg or 150 mg, determines which exact doses are given. }} | ||
Revision as of 14:02, 15 August 2011
| ||||||||||||||||||||||
| ||||||||||||||||||||||
Switch medication from trazodone to hypericum.[1] [2]
Stop trazodone - Before day 1: gradually reduce dosage of trazodone to a maximum of 150 mg/day, when this dosage is > 150 mg/day.
- Day 1: reduce dosage of trazodone to 75-100 mg/day.
- Day 8: stop administration of trazodone.
Start hypericum- Day 15: start administration of hypericum in a dosage of 300 mg three times a day (900 mg/day).[3][4][5][6]
More information- The content of trazodone in the tablet, for example 100 mg or 150 mg, determines which exact doses are given.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
- ↑ Imai H, Kotegawa T, Tsutsumi K, Morimoto T, Eshima N, Nakano S, Ohashi K. The recovery time-course of CYP3A after induction by St John's wort administration. Br J Clin Pharmacol. 2008 May;65(5):701-7.
- ↑ Wurglics M, Schubert-Zsilavecz M. Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet. 2006;45(5):449-68.
- ↑ Derijks HJ, Janknegt R, Heerdink ER, De Koning FH, Krekels MM, Looij BJ, Egberts AC. Influence of antidepressant use on glycemic control in patients with diabetes mellitus: an open-label comparative study. J Clin Psychopharmacol. 2009 Aug;29(4):405-8.
- ↑ KNMP; Informatorium Medicamentorum 2023; Monografie "trazodon" (Dutch)
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
